1. Home
  2. Directory
  3. Texas
  4. Houston
  5. Emergency Medicine
  6. NPI Profile
  7. Prescriptions 1386088045

ANDREW JOHN COYNE M.D.
Prescription History 1386088045
Emergency Medicine in Houston, TX

NPI Status: Active since April 24, 2013

Contact Information

6411 FANNIN ST
HOUSTON, TX
ZIP 77030
Phone: (713) 704-4060

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ANDREW JOHN COYNE M.D., an active Emergency Medicine specialist practicing in Houston, TX. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 51 documented patient claims. Among these therapy options, the most frequently utilized medication is Ondansetron Odt, which accounts for 20 claims alone.

Medication Index

D
H
O
No matching medications currently found on file.

Dicyclomine Hcl

Generic Formulation: Dicyclomine HclSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 80
TX State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills38.8
Peer Average Days Supply970
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.1% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $66.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.53

State Avg Cost Per Claim

$21.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Hydrocodone-Acetaminophen

Generic Formulation: Hydrocodone/AcetaminophenSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 69
TX State Average Benchmarks
Peer Average Claims121.0
Peer Average 30-Day Fills121.4
Peer Average Days Supply2,775
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 84.3% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $116.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.11

State Avg Cost Per Claim

$24.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to relieve moderate to severe pain. It contains an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen). Hydrocodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 67
TX State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills25.0
Peer Average Days Supply266
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $185.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.27

State Avg Cost Per Claim

$22.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ANDREW JOHN COYNE M.D. provides transparency into local medical care patterns within Houston, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Emergency Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.